Related Experiment Video

Updated: Apr 26, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy

Kulbhushan Tikoo1, Saritha Lodea1, Pinakin Arun Karpe1

  • 1Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Mohali, Punjab 160062, India.

Biochemical and Biophysical Research Communications
|July 19, 2014
PubMed

Insights

Roflumilast, a PDE 4 inhibitor, protects against diabetic nephropathy by reducing oxidative stress and apoptosis. It mimics calorie restriction effects via AMPK/SIRT1 activation, offering potential for metabolic disorder treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Background:

  • Diabetic nephropathy (DN) is a major complication of diabetes mellitus.
  • The role of phosphodiesterase 4 (PDE4) in DN pathogenesis remains largely unknown.
  • Selective PDE4 inhibition represents a potential therapeutic strategy for DN.

Purpose of the Study:

  • To investigate the therapeutic effect of roflumilast, a selective PDE4 inhibitor, in a rat model of type 1 diabetic nephropathy.
  • To elucidate the underlying mechanisms of roflumilast's protective effects in DN.

Main Methods:

  • Type 1 diabetes was induced in Sprague-Dawley rats using streptozotocin.
  • Rats were treated with roflumilast (2 and 3 mg/kg) or vehicle.
  • Kidney function, oxidative stress markers, extracellular matrix deposition, apoptosis, and key signaling pathways (AMPK, SIRT1, HO-1, FoxO1, NRF2) were assessed.

Main Results:

  • Roflumilast treatment normalized elevated plasma glucose, blood urea nitrogen, creatinine, and decreased plasma albumin in diabetic rats.
  • Roflumilast suppressed renal oxidative stress, fibronectin and collagen deposition, and apoptosis.
  • Roflumilast restored p-AMPK and SIRT1 levels, prevented HO-1 increase, and FoxO1 loss, but did not affect NRF2 levels.

Conclusions:

  • Roflumilast exhibits significant renoprotective effects in type 1 diabetic nephropathy.
  • The protective mechanisms involve mimicking calorie restriction through AMPK/SIRT1 activation.
  • Roflumilast demonstrates potential as a therapeutic agent for diabetic nephropathy and other metabolic disorders.
Keywords:
AMPK and SIRT1Calorie restrictionDiabetic nephropathyPDE4

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.1K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
26
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
48
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
42